首页> 外文期刊>Journal of Pharmacy and Bioallied Sciences >Does atorvastatin work more effectively than biguanides in reducing cardiovascular risk factors?
【24h】

Does atorvastatin work more effectively than biguanides in reducing cardiovascular risk factors?

机译:阿托伐他汀在降低心血管疾病危险因素方面比双胍类更有效吗?

获取原文
           

摘要

Increased risk of coronary artery disease in diabetic persons is associated with increased level of lipoproteins. Usually, such risks are reverted with glycemic control by antidiabetic medicines in Type I diabetes millitus. However, in Type II diabetes mellitus lipid values can be improved using antidiabetics but still the risk of coronary artery disease remains. The initial approach for reducing lipid contents in diabetic patients should include glycemic control, diet, weight loss, and exercise. But if it fails then lipid-lowering agents like fibrate and HMG CoA reductase (3-hydroxy-3-methyl-glutaryl-CoA reductase) inhibitors should work effectively. In the present study results of atorvastatin compared with biguanides proved atorvastatin as a more effective lipid-lowering agent along with antidiabetic activity so it can effectively help in reducing the risk of cardiovascular disease (CVD).Keywords: Atorvastatin, biguanides, cardiovascular disorders, 3-hydroxy-3-methyl-glutaryl-CoA reductase
机译:糖尿病人患冠状动脉疾病的风险增加与脂蛋白水平增加有关。通常,在I型糖尿病患者中,通过降糖药物控制血糖可逆转此类风险。然而,在II型糖尿病中,可以通过使用抗糖尿病药物来改善血脂水平,但仍然存在冠心病的风险。降低糖尿病患者脂质含量的最初方法应包括血糖控制,饮食,减肥和运动。但是,如果失败了,那么降血脂药,如贝特类和HMG CoA还原酶(3-羟基-3-甲基-戊二酰-CoA还原酶)抑制剂应能有效发挥作用。在本研究中,阿托伐他汀与双胍类药物的比较证明了阿托伐他汀是一种更有效的降血脂药,同时具有抗糖尿病活性,因此可以有效帮助降低心血管疾病(CVD)的风险。关键词:阿托伐他汀,双胍类药物,心血管疾病,3 -羟基-3-甲基-戊二酰辅酶A还原酶

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号